Log in
Fluorescence lifetime research since 1993 in Strathclyde's Photophysics Group led by Prof. David Birch contributed to the success of the University spin-out company IBH (Imhof, Birch, Hallam), and its successful merger with the £1Bn multinational company Horiba. The Strathclyde research has helped Horiba to be, since 2008, the market-leading supplier of fluorescence spectrometers, which comprise steady-state, lifetime and hybrid instruments. The commercial success of the company has led to economic benefits and employment. Through production of an improved spectrometry product range, the Strathclyde research has also facilitated multidisciplinary molecular and materials research globally, across Industry, Government and University sectors, bringing benefits to diverse disciplines such as life sciences, healthcare, chemistry, and nanotechnology.
Imperial researchers in Prof Paul French's photonics group demonstrated one of the first practical FLIM instruments in 1997 using a prototype gated optical intensifier (GOI) developed by Kentech Instruments Ltd and a home-built solid-state ultrafast laser. They subsequently pioneered the use of ultrafast supercontinuum sources (USS) for FLIM. Today wide-field time-gated FLIM is a commercial success and is being widely applied for biomedicine, including for imaging of diseased tissue [e.g. 5] and for FRET (Fluorescence resonance energy transfer) microscopy to assay protein interactions [e.g. 3, 4]. This research thus helped translate FLIM to a wider community, highlighting the potential for tissue imaging, cell biology and drug discovery. It stimulated about £5M of GOI sales for Kentech [section 5, source A], with whom they developed time-gated FLIM technology and applications, and millions of pounds worth of sales of supercontinuum sources for Fianium Ltd [B].
Aurox Ltd is an Oxfordshire spin-out company formed in 2004 by Prof Mark Neil (at Imperial since August 2002) with former colleagues from Oxford University. Its main product line consists of wide field optical sectioning fluorescence microscopes based on the principle of structured illumination and detection using patterned disks. The microscopes use conventional (lower cost) light sources and do not require a scanning system which sets them apart from competitors. Research at Imperial has impacted on the design of disk patterns for optimising performance and has played a critical role in bringing these microscopes to market. Aurox's systems are supplied to and marketed by Carl Zeiss (as VivaTome™) and Andor Technology (as Revolution DSD™) for application in the biomedical sciences, generating successful sales over the period 2008-2012 and enabling Aurox to embark on a second-generation development programme. Since 2008 Aurox have sold more than 150 units with market value in excess of £3M. The majority of this £3M in sales have been since 2010 when an optimisation step which was developed and devised at Imperial College was incorporated into the Aurox products.
Since the 1990s, the threat from malevolent release of airborne pathogens has grown in military and civilian contexts. However, solid-state UV lasers, central to the preferred fluorescence detection technologies, were prohibitively expensive for use in `low-cost' detectors. In 2001, Hertfordshire researchers proposed an alternative based on inexpensive xenon flashlamp sources, commonly used in disposable cameras. Between 2001 and 2006, they developed and optimised this approach, with the resulting `WIBS' technology now a core part of the UK military's bioaerosol defence programme and patented worldwide. The technology's affordability also has led to its growing international use in areas such as atmospheric science, climate research, and occupational health. In 2012, a commercial licence was purchased by a leading US instrumentation company to exploit in the field of atmospheric and climate science; discussions with further licensees to exploit in other fields are continuing.
Pioneering research at Essex developed an innovative mathematical method for determining the chlorophyll fluorescence parameter Fo', as well as novel LED lighting technology and a multi-plant imaging system. This instrument is marketed by Technologica. Originally an Essex spinout, the company has sold 42 units across Europe, Asia and South America since 2006, recording its highest ever profits over the past three years (totalling ~£115k). Essex's mathematical method for determining Fo' is also used by other manufacturers, who have since developed their own imaging systems. This research has helped to establish chlorophyll fluorescence imaging as a mainstream screening tool, now used globally to inform a range of crop production and handling strategies.
The development by Cambridge University staff of compact semiconductor sources and detectors of Terahertz radiation has opened up this part of the electromagnetic spectrum to commercial use for the first time, enabling many applications. In medicine these applications include the analysis of drugs and the detection and imaging of cancer; in security applications the detection and imaging of explosives; and in the semiconductor industry the detection and imaging of buried defects in semiconductor wafers. High power Terahertz lasers are used in gas sensors, for imaging and as local oscillators. This technology has been exploited by a spin-off company TeraView which has 25 employees, has raised £16M in funding, £3.5M since 2008, and has sold 70 imaging systems, half since 2008 at an average cost of $300K each.
Professors Zhelev (UoA5) and Bradley (UoA15) explored the scope and demonstrated the feasibility of using light-scattering methods for quantitative analysis of macromolecular associations and aggregation, including protein-protein and protein-DNA interactions. 16 years of design and development research was translated into a marketed product — the PAM™Zero — a novel hand-held, low-cost protein aggregation monitor capable of detecting macromolecule aggregation in microliter sample volumes. Manufactured and sold through a spinout company, Norton Scientific Inc. (established in 2010 and valued at $7M), this portable instrument is used in commercial Quality Control and academic research and has been sold to a range of stakeholders e.g. drug development companies, for food safety and water pollution monitoring.
Impact: Commerce and professional services; the development of Optical Projection Tomography (OPT) — a technique for three-dimensional (3D) optical microscopy.
Significance: A step-change in scientific imaging; novel equipment and training services for imaging laboratories, offering a new standard in 3D microscopy. Over £2M in sales for the MRC.
Beneficiaries: Scientific institutions and imaging facilities, commerce.
Attribution: OPT was developed, by Sharpe, Baldock and Davidson, and commercialised at the MRC Human Genetics Unit, UoE.
Reach: World-wide: OPT instruments are used in Europe, America, Asia and Australia; chapters on OPT can be found in major microscopy textbooks.
The commercialisation of Quantum Cascade Lasers (QCL) and the associated novel fabrication processes developed at the University of Glasgow has provided Compound Semiconductor Technologies Global Ltd (CSTG) with a new foundry product supplying quantum cascade lasers for gas sensing, safety and security, and military applications. This resulted in 40% turnover growth from 2010-2012 and the company is now recognised as a global leader in QCLs and their fabrication. Based on University of Glasgow research, the company has created a manufacturing toolbox for the production of a wide variety of QCL chip designs. CSTG has also achieved a world first, manufacturing QCLs for systems that detect explosives at a safe distance and can counter heat-seeking missile attacks on aircraft.
Research in protein folding and technological development at the University of Leeds led to the creation of Optim1000, a high throughput microlitre protein stability analyser, through Leeds spin-off company Avacta. Used in the early stages of R&D in the biopharma industry, Optim1000 evaluates the stability and homogeneity of complex biological drugs, using just micrograms of protein sample. This screening reduces the costly development and late-stage failure of unsuitable candidate therapeutics. The platform has been sold to a wide range of global biopharma companies; it is reported to reduce drug stability screening by months. This provides economic impact through saving the industry millions of dollars in R&D costs, along with health impact by speeding up the emergence of new products. Avacta reported revenue of over £3 million in 2012 and employs 70 staff.